Adicet Bio Stock Fundamentals
| ACET Stock | USD 1.45 0.03 2.03% |
Adicet Bio fundamentals help investors to digest information that contributes to Adicet Bio's financial success or failures. It also enables traders to predict the movement of Adicet Stock. The fundamental analysis module provides a way to measure Adicet Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adicet Bio stock.
At this time, Adicet Bio's Selling General Administrative is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 181.5 M in 2024, whereas Total Revenue is likely to drop 0.00 in 2024. Adicet | Select Account or Indicator |
Adicet Bio Company Shares Owned By Insiders Analysis
Adicet Bio's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Adicet Bio Shares Owned By Insiders | 1.59 % |
Most of Adicet Bio's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adicet Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 1.59% of Adicet Bio are shares owned by insiders. This is 89.53% lower than that of the Health Care Providers & Services sector and 88.79% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 84.24% higher than that of the company.
Adicet Bio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Adicet Bio's current stock value. Our valuation model uses many indicators to compare Adicet Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adicet Bio competition to find correlations between indicators driving Adicet Bio's intrinsic value. More Info.Adicet Bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Adicet Bio's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adicet Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Adicet Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adicet Bio's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adicet Bio could also be used in its relative valuation, which is a method of valuing Adicet Bio by comparing valuation metrics of similar companies.Adicet Bio is currently under evaluation in shares owned by insiders category among its peers.
Adicet Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adicet Bio from analyzing Adicet Bio's financial statements. These drivers represent accounts that assess Adicet Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adicet Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 156.2M | 102.8M | 541.4M | 367.3M | 81.4M | 77.3M | |
| Enterprise Value | 259.6M | 40.2M | 284.8M | 130.6M | (57.4M) | (54.6M) |
Adicet Fundamentals
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (82.98 M) | ||||
| Shares Outstanding | 82.4 M | ||||
| Shares Owned By Insiders | 1.59 % | ||||
| Shares Owned By Institutions | 76.37 % | ||||
| Number Of Shares Shorted | 3.72 M | ||||
| Price To Earning | 36.84 X | ||||
| Price To Book | 0.52 X | ||||
| Price To Sales | 9.72 X | ||||
| Gross Profit | 24.99 M | ||||
| EBITDA | (126.48 M) | ||||
| Net Income | (142.66 M) | ||||
| Cash And Equivalents | 260.64 M | ||||
| Cash Per Share | 6.11 X | ||||
| Total Debt | 20.92 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 16.10 X | ||||
| Book Value Per Share | 2.85 X | ||||
| Cash Flow From Operations | (93.72 M) | ||||
| Short Ratio | 9.15 X | ||||
| Earnings Per Share | (2.52) X | ||||
| Price To Earnings To Growth | 0.82 X | ||||
| Target Price | 6.4 | ||||
| Number Of Employees | 143 | ||||
| Beta | 1.69 | ||||
| Market Capitalization | 119.48 M | ||||
| Total Asset | 207.29 M | ||||
| Retained Earnings | (380.77 M) | ||||
| Working Capital | 142.99 M | ||||
| Current Asset | 352.66 M | ||||
| Current Liabilities | 98.91 M | ||||
| Five Year Return | 3.23 % | ||||
| Net Asset | 207.29 M |
About Adicet Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adicet Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adicet Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adicet Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 5.5 M | 3.6 M | |
| Cost Of Revenue | 6.1 M | 5.8 M | |
| Stock Based Compensation To Revenue | 0.62 | 0.50 | |
| Sales General And Administrative To Revenue | 0.95 | 0.83 | |
| Research And Ddevelopement To Revenue | 2.57 | 2.58 | |
| Capex To Revenue | 0.60 | 0.63 | |
| Revenue Per Share | 0.70 | 0.66 | |
| Ebit Per Revenue | (3.34) | (3.51) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.